ATATcH Alternating Treatment Plans for Advanced Cancer
NCT05358548
This study is recruiting at 10 US sites in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of the research is to evaluate a new schedule of alternating cycles of induction chemoimmunotherapy (chemotherapy plus pembrolizumab) and immunotherapy (pembrolizumab) alone for the initial treatment of patients with advanced lung or head and neck cancers.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Head and Neck Cancer
- Lung Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Rutgers, The State University of New Jersey
- Last updated on ClinicalTrials.gov
- April 30, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
New Jersey · 10
- Trinitas Hospital and Comprehensive Cancer Center · Elizabeth, NJ
- Cancer Institute of New Jersey at Hamilton · Hamilton, NJ
- RWJBarnabas Health - Jersey City · Jersey City, NJ
- RWJBarnabas Health - Monmouth Medical Center Southern Campus · Lakewood, NJ
- RWJBarnabas Health - Saint Barnabas Medical Center · Livingston, NJ
- RWJBarnabas Health - Monmouth Medical Center · Long Branch, NJ
- Rutgers Cancer Institute of New Jersey · New Brunswick, NJ
- RWJBarnabas Health - Newark Beth Israel Medical Center · Newark, NJ
- Robert Wood Johnson Somerset Hospital · Somerville, NJ
- RWJBarnabas Health - Community Medical Center · Toms River, NJ
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.